-
1
-
-
77953702668
-
Acute myeloid leukemia and the Wnt pathway
-
1:CAS:528:DC%2BC3cXnvVakurY%3D 20554989
-
Eaves CJ, Humphries RK. Acute myeloid leukemia and the Wnt pathway. N Engl J Med. 2010;362:2326-7.
-
(2010)
N Engl J Med
, vol.362
, pp. 2326-2327
-
-
Eaves, C.J.1
Humphries, R.K.2
-
2
-
-
77449159028
-
Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet
-
19880497
-
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-74.
-
(2010)
Blood
, vol.115
, pp. 453-474
-
-
Döhner, H.1
Estey, E.H.2
Amadori, S.3
Appelbaum, F.R.4
Büchner, T.5
Burnett, A.K.6
-
3
-
-
22644445408
-
Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
-
1:STN:280:DyaK283ms1Cquw%3D%3D 8667648
-
List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996;10:937-42.
-
(1996)
Leukemia
, vol.10
, pp. 937-942
-
-
List, A.F.1
-
4
-
-
0030789242
-
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
-
1:CAS:528:DyaK2sXkt1GrtLY%3D 9212098
-
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-7.
-
(1997)
Nat Med
, vol.3
, pp. 730-737
-
-
Bonnet, D.1
Dick, J.E.2
-
5
-
-
77950867732
-
Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells
-
1:CAS:528:DC%2BC3cXkvFChu78%3D 20350531
-
Fuchs D, Daniel V, Sadeqhi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010;394:1098-104.
-
(2010)
Biochem Biophys Res Commun
, vol.394
, pp. 1098-1104
-
-
Fuchs, D.1
Daniel, V.2
Sadeqhi, M.3
Opelz, G.4
Naujokat, C.5
-
6
-
-
84907203427
-
Association of a murine leukaemia stem cell gene signature based on nucleostemin promoter activity with prognosis of acute myeloid leukaemia in patients
-
1:CAS:528:DC%2BC2cXhtFans7jJ 24960197
-
Ali MA, Naka K, Yoshida A, Fuse K, Kasada A, Hoshii T, et al. Association of a murine leukaemia stem cell gene signature based on nucleostemin promoter activity with prognosis of acute myeloid leukaemia in patients. Biochem Biophys Res Commun. 2014;450:837-43.
-
(2014)
Biochem Biophys Res Commun
, vol.450
, pp. 837-843
-
-
Ali, M.A.1
Naka, K.2
Yoshida, A.3
Fuse, K.4
Kasada, A.5
Hoshii, T.6
-
7
-
-
79952282655
-
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cell
-
1:CAS:528:DC%2BC3cXhsVWmurnK 21076471
-
Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cell. Oncogene. 2011;30:1009-19.
-
(2011)
Oncogene
, vol.30
, pp. 1009-1019
-
-
Majeti, R.1
-
8
-
-
1242307379
-
Interleukin-3 receptor in acute leukemia
-
1:CAS:528:DC%2BD2cXlt1agsQ%3D%3D 14671644
-
Testa U, Riccioni R, Diverio D, Rossini A, Lo Coco F, Peschle C. Interleukin-3 receptor in acute leukemia. Leukemia. 2004;18:219-26.
-
(2004)
Leukemia
, vol.18
, pp. 219-226
-
-
Testa, U.1
Riccioni, R.2
Diverio, D.3
Rossini, A.4
Lo Coco, F.5
Peschle, C.6
-
9
-
-
67649200331
-
Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells
-
1:CAS:528:DC%2BD1MXoslCnsrY%3D 19570512
-
Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5:31-42.
-
(2009)
Cell Stem Cell
, vol.5
, pp. 31-42
-
-
Jin, L.1
Lee, E.M.2
Ramshaw, H.S.3
Busfield, S.J.4
Peoppl, A.G.5
Wilkinson, L.6
-
10
-
-
0034119046
-
Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias
-
1:CAS:528:DC%2BD3cXivFOhurw%3D 10764142
-
Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia. 2000;14:576-85.
-
(2000)
Leukemia
, vol.14
, pp. 576-585
-
-
Frankel, A.E.1
McCubrey, J.A.2
Miller, M.S.3
Delatte, S.4
Ramage, J.5
Kiser, M.6
-
11
-
-
0037085927
-
A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors
-
1:CAS:528:DC%2BD38XisVSisbY%3D 11912147
-
Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res. 2002;62:1730-6.
-
(2002)
Cancer Res
, vol.62
, pp. 1730-1736
-
-
Feuring-Buske, M.1
Frankel, A.E.2
Alexander, R.L.3
Gerhard, B.4
Hogge, D.E.5
-
12
-
-
84877070912
-
Cancer immunotherapy
-
1:CAS:528:DC%2BC3sXmtVansLw%3D 23587868
-
Gajewski TF, Schumacher T. Cancer immunotherapy. Curr Opin Immunol. 2013;25:259-60.
-
(2013)
Curr Opin Immunol
, vol.25
, pp. 259-260
-
-
Gajewski, T.F.1
Schumacher, T.2
-
13
-
-
42449094497
-
Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model
-
1:CAS:528:DC%2BD1cXlslCqtrY%3D 18364239
-
Rinaldi M, Fioretti D, Iurescia S, Signori E, Pierimarchi P, Seripa D, et al. Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model. Biochem Biophys Res Commun. 2008;370:279-84.
-
(2008)
Biochem Biophys Res Commun
, vol.370
, pp. 279-284
-
-
Rinaldi, M.1
Fioretti, D.2
Iurescia, S.3
Signori, E.4
Pierimarchi, P.5
Seripa, D.6
-
14
-
-
0035655587
-
The immunological synapse of CTL contains a secretory domain and membrane bridges
-
1:CAS:528:DC%2BD3MXptVGgtb8%3D 11728337
-
Stinchcombe JC, Bossi G, Booth S, Griffiths GM. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity. 2001;15:751-61.
-
(2001)
Immunity
, vol.15
, pp. 751-761
-
-
Stinchcombe, J.C.1
Bossi, G.2
Booth, S.3
Griffiths, G.M.4
-
15
-
-
51649124273
-
Double whammy: Bispecific antibodies help immune cells attack tumors
-
1:CAS:528:DC%2BD1cXhtFCnsrzE 18804023
-
Shekhar C. Double whammy: bispecific antibodies help immune cells attack tumors. Chem Biol. 2008;15:877-8.
-
(2008)
Chem Biol
, vol.15
, pp. 877-878
-
-
Shekhar, C.1
-
16
-
-
84875955851
-
Redirection of T-cell effector functions for cancer therapy: Bispecific antibodies and chimeric antigen receptors
-
1:CAS:528:DC%2BC3sXlsVCksLk%3D 23560375
-
Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncol. 2013;9:527-39.
-
(2013)
Future Oncol
, vol.9
, pp. 527-539
-
-
Satta, A.1
Mezzanzanica, D.2
Turatti, F.3
Canevari, S.4
Figini, M.5
-
17
-
-
84866996937
-
Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells
-
1:CAS:528:DC%2BC38XhsVehtLzP 22740616
-
Kuo SR, Wong L, Liu JS. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng Des Sel. 2012;25:561-9.
-
(2012)
Protein Eng des Sel
, vol.25
, pp. 561-569
-
-
Kuo, S.R.1
Wong, L.2
Liu, J.S.3
-
18
-
-
84888226232
-
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
-
3814731 1:CAS:528:DC%2BC3sXhslGhtbfK 24030378
-
Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138-48.
-
(2013)
Blood
, vol.122
, pp. 3138-3148
-
-
Mardiros, A.1
Dos Santos, C.2
McDonald, T.3
Brown, C.E.4
Wang, X.5
Budde, L.E.6
-
19
-
-
84876163922
-
Targeting of acute myeloid leukemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor
-
1:CAS:528:DC%2BC3sXlvVensLc%3D 23432359
-
Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, et al. Targeting of acute myeloid leukemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161:389-401.
-
(2013)
Br J Haematol
, vol.161
, pp. 389-401
-
-
Tettamanti, S.1
Marin, V.2
Pizzitola, I.3
Magnani, C.F.4
Giordano Attianese, G.M.5
Cribioli, E.6
-
20
-
-
0037226562
-
Interleukin-3 promotes proliferation and differentiation of human hematopoietic stem cells but reduces their repopulation potential in NOD/SCID mice
-
1:CAS:528:DC%2BD3sXis1Gmt74%3D 12634420
-
Nitsche A, Junghahn I, Thulke S, Aumann J, Radonić A, Fichtner I, et al. Interleukin-3 promotes proliferation and differentiation of human hematopoietic stem cells but reduces their repopulation potential in NOD/SCID mice. Stem Cells. 2003;21:236-44.
-
(2003)
Stem Cells
, vol.21
, pp. 236-244
-
-
Nitsche, A.1
Junghahn, I.2
Thulke, S.3
Aumann, J.4
Radonić, A.5
Fichtner, I.6
-
21
-
-
0037810249
-
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention
-
1:CAS:528:DC%2BD3sXkvFeqsro%3D 12835716
-
Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003;17:1263-93.
-
(2003)
Leukemia
, vol.17
, pp. 1263-1293
-
-
Chang, F.1
Steelman, L.S.2
Lee, J.T.3
Shelton, J.G.4
Navolanic, P.M.5
Blalock, W.L.6
-
22
-
-
0027085704
-
A human interleukin 3 analog with increased biological and binding activities
-
50653 1:CAS:528:DyaK3sXnvFSqug%3D%3D 1465408
-
Lopez AF, Shannon MF, Barry S, Phillips JA, Cambareri B, Dottore M, et al. A human interleukin 3 analog with increased biological and binding activities. Proc Natl Acad Sci U S A. 1992;89:11842-6.
-
(1992)
Proc Natl Acad Sci U S A
, vol.89
, pp. 11842-11846
-
-
Lopez, A.F.1
Shannon, M.F.2
Barry, S.3
Phillips, J.A.4
Cambareri, B.5
Dottore, M.6
-
23
-
-
0032745326
-
Use of combinatorial mutagenesis to select for multiply substituted human interleukin-3 variants with improved pharmacologic properties
-
1:CAS:528:DC%2BD3cXjt1ymtA%3D%3D 10641592
-
Klein BK, Olins PO, Bauer SC, Caparon MH, Easton AM, Braford SR, et al. Use of combinatorial mutagenesis to select for multiply substituted human interleukin-3 variants with improved pharmacologic properties. Exp Hematol. 1999;27:1746-56.
-
(1999)
Exp Hematol
, vol.27
, pp. 1746-1756
-
-
Klein, B.K.1
Olins, P.O.2
Bauer, S.C.3
Caparon, M.H.4
Easton, A.M.5
Braford, S.R.6
-
24
-
-
0030928120
-
The receptor binding site of human interleukin-3 defined by mutagenesis and molecular modeling
-
1:CAS:528:DyaK2sXlvFGitLg%3D 9278420
-
Klein BK, Feng Y, McWherter CA, Hood WF, Paik K, McKearn JP. The receptor binding site of human interleukin-3 defined by mutagenesis and molecular modeling. J Biol Chem. 1997;272:22630-41.
-
(1997)
J Biol Chem
, vol.272
, pp. 22630-22641
-
-
Klein, B.K.1
Feng, Y.2
McWherter, C.A.3
Hood, W.F.4
Paik, K.5
McKearn, J.P.6
-
25
-
-
1542267419
-
Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity
-
1:CAS:528:DC%2BD2cXhslChsLs%3D 15003313
-
Liu TF, Urieto JO, Moore JE, Miller MS, Lowe AC, Thorburn A, et al. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol. 2004;32:277-81.
-
(2004)
Exp Hematol
, vol.32
, pp. 277-281
-
-
Liu, T.F.1
Urieto, J.O.2
Moore, J.E.3
Miller, M.S.4
Lowe, A.C.5
Thorburn, A.6
-
26
-
-
84855166689
-
Recent advance in antigen-specific immunotherapy for acute myeloid leukemia
-
3199067 22028726
-
Kadowaki N, Kitawaki T. Recent advance in antigen-specific immunotherapy for acute myeloid leukemia. Clin Dev Immunol. 2011;2011:104926.
-
(2011)
Clin Dev Immunol
, vol.2011
, pp. 104926
-
-
Kadowaki, N.1
Kitawaki, T.2
-
27
-
-
78649686241
-
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells
-
1:CAS:528:DC%2BC3cXhsVygs7vM 21112565
-
Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7:708-17.
-
(2010)
Cell Stem Cell
, vol.7
, pp. 708-717
-
-
Kikushige, Y.1
Shima, T.2
Takayanagi, S.3
Urata, S.4
Miyamoto, T.5
Iwasaki, H.6
-
28
-
-
0035662980
-
Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies
-
Muñoz L, Nomdedéu JF, López O, Carnicer MJ, Bellido M, Aventín A, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261-9.
-
(2001)
Haematologica
, vol.86
, pp. 1261-1269
-
-
Muñoz, L.1
Nomdedéu, J.F.2
López, O.3
Carnicer, M.J.4
Bellido, M.5
Aventín, A.6
-
29
-
-
0037108559
-
Elevated expression of IL-3R alpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis
-
1:CAS:528:DC%2BD38XotVGhtL8%3D 12351411
-
Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P, et al. Elevated expression of IL-3R alpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980-8.
-
(2002)
Blood
, vol.100
, pp. 2980-2988
-
-
Testa, U.1
Riccioni, R.2
Militi, S.3
Coccia, E.4
Stellacci, E.5
Samoggia, P.6
-
30
-
-
79955952683
-
Overexpression of IL-3Rα on CD34 + CD38- stem cells defines leukemia- initiating cells in Fanconi anemia AML
-
3087476 1:CAS:528:DC%2BC3MXls1Giur0%3D 21330473
-
Du W, Li XE, Sipple J, Pang Q. Overexpression of IL-3Rα on CD34 + CD38- stem cells defines leukemia- initiating cells in Fanconi anemia AML. Blood. 2011;117:4243-52.
-
(2011)
Blood
, vol.117
, pp. 4243-4252
-
-
Du, W.1
Li, X.E.2
Sipple, J.3
Pang, Q.4
-
31
-
-
70349786183
-
Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli
-
1:CAS:528:DC%2BD1MXhtVWisbrL 19259665
-
Liu J, Yang M, Wang J, Xu Y, Wang Y, Shao X, et al. Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli. Cancer Immunol Immunother. 2009;58:1761-9.
-
(2009)
Cancer Immunol Immunother
, vol.58
, pp. 1761-1769
-
-
Liu, J.1
Yang, M.2
Wang, J.3
Xu, Y.4
Wang, Y.5
Shao, X.6
-
32
-
-
84879245589
-
Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity
-
Wei L, Dongmei F, Ming Y, Ruizan S, Yan Y, Linlin J, et al. Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity. Cell Oncol (Dordr). 2012;35:423-34.
-
(2012)
Cell Oncol (Dordr)
, vol.35
, pp. 423-434
-
-
Wei, L.1
Dongmei, F.2
Ming, Y.3
Ruizan, S.4
Yan, Y.5
Linlin, J.6
-
33
-
-
84891624172
-
HMICL and CD123 in combination with a CD45/CD34/CD117 backbone - A universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia
-
1:CAS:528:DC%2BC2cXktFWgtw%3D%3D 24152218
-
Roug AS, Larsen HØ, Nederby L, Just T, Brown G, Nyvold CG, et al. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia. Br J Haematol. 2014;164:212-22.
-
(2014)
Br J Haematol
, vol.164
, pp. 212-222
-
-
Roug, A.S.1
Larsen HØ.2
Nederby, L.3
Just, T.4
Brown, G.5
Nyvold, C.G.6
-
34
-
-
0035884392
-
The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes
-
1:CAS:528:DC%2BD3MXntFaisbk%3D 11559560
-
Brossart P, Schneider A, Dill P, Schammann T, Grünebach F, Wirths S, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001;61:6846-50.
-
(2001)
Cancer Res
, vol.61
, pp. 6846-6850
-
-
Brossart, P.1
Schneider, A.2
Dill, P.3
Schammann, T.4
Grünebach, F.5
Wirths, S.6
-
35
-
-
67650632683
-
CD47 is an adverse prognostic factor and therapeutics antibody target on human acute myeloid leukemia stem cells
-
2726837 1:CAS:528:DC%2BD1MXhtVSgtr3N 19632179
-
Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs Jr KD, et al. CD47 is an adverse prognostic factor and therapeutics antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286-99.
-
(2009)
Cell
, vol.138
, pp. 286-299
-
-
Majeti, R.1
Chao, M.P.2
Alizadeh, A.A.3
Pang, W.W.4
Jaiswal, S.5
Gibbs, Jr.K.D.6
-
36
-
-
69449091993
-
Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells
-
2738247 1:CAS:528:DC%2BD1MXhtFSgt73M 19587053
-
Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol. 2009;83:9122-30.
-
(2009)
J Virol
, vol.83
, pp. 9122-9130
-
-
Golden-Mason, L.1
Palmer, B.E.2
Kassam, N.3
Townshend-Bulson, L.4
Livingston, S.5
McMahon, B.J.6
-
37
-
-
78649814615
-
Harnessing the immune response to treat cancer
-
1:CAS:528:DC%2BC3cXhtFOht7vL 20856204
-
Steer HJ, Lake RA, Nowak AK, Robinson BW. Harnessing the immune response to treat cancer. Oncogene. 2010;29:6301-13.
-
(2010)
Oncogene
, vol.29
, pp. 6301-6313
-
-
Steer, H.J.1
Lake, R.A.2
Nowak, A.K.3
Robinson, B.W.4
-
38
-
-
82955207691
-
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
-
3234664 1:CAS:528:DC%2BC3MXhs1ansb3O 21984804
-
Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118:6050-6.
-
(2011)
Blood
, vol.118
, pp. 6050-6056
-
-
Louis, C.U.1
Savoldo, B.2
Dotti, G.3
Pule, M.4
Yvon, E.5
Myers, G.D.6
-
39
-
-
80455179612
-
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
-
3208293 1:CAS:528:DC%2BC3MXhsVOgsrjL 21849486
-
Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817-28.
-
(2011)
Blood
, vol.118
, pp. 4817-4828
-
-
Brentjens, R.J.1
Rivière, I.2
Park, J.H.3
Davila, M.L.4
Wang, X.5
Stefanski, J.6
-
40
-
-
77950475517
-
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB
-
2862534 1:CAS:528:DC%2BC3cXitlaitb4%3D 20179677
-
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB. Mol Ther. 2010;18:843-51.
-
(2010)
Mol Ther
, vol.18
, pp. 843-851
-
-
Morgan, R.A.1
Yang, J.C.2
Kitano, M.3
Dudley, M.E.4
Laurencot, C.M.5
Rosenberg, S.A.6
-
41
-
-
84863522243
-
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
-
1:CAS:528:DC%2BC38XhtFSgtL7F 22592608
-
Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226-33.
-
(2012)
Blood
, vol.119
, pp. 6226-6233
-
-
Klinger, M.1
Brandl, C.2
Zugmaier, G.3
Hijazi, Y.4
Bargou, R.C.5
Topp, M.S.6
-
42
-
-
33644755626
-
Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors
-
1:CAS:528:DC%2BD28XhsFaltbo%3D 16489085
-
Hogge DE, Yalcintepe L, Wong SH, Gerhard B, Frankel AE. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res. 2006;12:1284-91.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 1284-1291
-
-
Hogge, D.E.1
Yalcintepe, L.2
Wong, S.H.3
Gerhard, B.4
Frankel, A.E.5
-
43
-
-
3142758688
-
Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells
-
1:CAS:528:DC%2BD2cXkvF2ku7s%3D 15152266
-
Vereecque R, Saudemout A, Quesnel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia. 2004;18:1223-30.
-
(2004)
Leukemia
, vol.18
, pp. 1223-1230
-
-
Vereecque, R.1
Saudemout, A.2
Quesnel, B.3
-
44
-
-
0027616965
-
A high affinity CD3 monoclonal antibody HIT3a
-
1:CAS:528:DyaK2cXlt1aiug%3D%3D 8221997
-
Shen D. A high affinity CD3 monoclonal antibody HIT3a. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1993;15:157-62.
-
(1993)
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
, vol.15
, pp. 157-162
-
-
Shen, D.1
-
45
-
-
33645007038
-
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
-
1:CAS:528:DC%2BD28Xitl2murg%3D 16032400
-
Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother. 2006;55:503-14.
-
(2006)
Cancer Immunol Immunother
, vol.55
, pp. 503-514
-
-
Schlereth, B.1
Quadt, C.2
Dreier, T.3
Kufer, P.4
Lorenczewski, G.5
Prang, N.6
|